This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Confidence in ONXX/AMGN Deal

TheStreet Premium Services

A complimentary preview
of Options-Profits Previews

Headquartered in San Francisco, CA, Onyx Pharmaceuticals (ONXX) is a biopharmaceutical company involved in the development of therapies that target molecular mechanisms that cause cancer. Shares have outperformed in 2013 and are up 52.5% year-to-date to $115.22. Some players in the options market seem to be anticipating additional gains for the stock in the weeks ahead, as Sep 120 and 125 calls on the stock drew heavy trading Friday.

ONXX gapped up 54.1% on July 1st on reports Amgen (AMGN) wants to buy the company for $120 per share. The stock rallied to a record high of $136.87 through July 8 and remained well above the offering price in the weeks that followed on expectations other bidders might top AMGN's offer. On July 16, ONXX said it was expecting to see interest from roughly five parties, including Pfizer (PFE).

ONXX is down $0.40 to $115.40 today and took a 7.3% hit last Thursday after Bloomberg reported that the biotech's merger talks with AMGN might have hit a snag. The article noted that, while AMGN is possibly willing to raise its offer to $130 per share, the deal might collapse over AMGN's put to access data related to ONXX blood cancer treatment Kyprolis, the company's key attraction.

While ONXX shares are now trading well below the $120 original offer on concerns the deal might collapse, some players in the options market seem to be expecting a deal announcement in the weeks ahead. On Friday, 53,000 calls and 31,000 puts traded on the stock. Much of the focus was on September 120 and 125 calls, with buyers taking new positions. Some of the activity might have been to replace August upside calls on ONXX that expired last week. Nevertheless, the activity seems to be expressing confidence that a deal could take place at a price much higher than current levels and an announcement will happen before the September expiration.

OptionsProfits can be followed on Twitter at twitter.com/OptionsProfits

Henry can be followed on Twitter at twitter.com/OptionAlert

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

At the time of publication, Henry Schwartz held no positions in the stocks or issues mentioned.


Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
Top Rated Stocks Top Rated Funds Top Rated ETFs